CC
AMLX icon

Commodore Capital’s Amylyx Pharmaceuticals AMLX Stock Holding History

Commodore Capital’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$101M Hold
5,650,000
– – 6.04% 5
2026
Q1 		$78.5M Hold
5,650,000
– – 4.54% 9
2025
Q4 		$68.3M Buy
5,650,000
+1,574,522
+39% +$21.4M 4.54% 9
2025
Q3 		$55.4M Buy
+4,075,478
New +$38.4M 2.7% 16

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Commodore Capital's AMLX Position: Q2 2026 in Review

Commodore Capital held its Amylyx Pharmaceuticals (AMLX) position steady in Q2 2026 at 5,650,000 shares worth $101M. The position accounts for 6.04% of the portfolio, ranked #5.

Commodore Capital first reported a position in AMLX in Q3 2025 and has held it in 4 quarters since. 207 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Commodore Capital held 5,650,000 shares of Amylyx Pharmaceuticals worth $101M as of Q2 2026.
  • Commodore Capital left its Amylyx Pharmaceuticals share count unchanged in Q2 2026.
  • Amylyx Pharmaceuticals made up 6.04% of Commodore Capital's portfolio in Q2 2026, its #5 holding.
  • Commodore Capital first reported a position in Amylyx Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 207 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Commodore Capital's 13F filing for Q2 2026, filed 14 Aug 2026.